Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;102(2):442-444.
doi: 10.1016/j.kint.2022.05.008. Epub 2022 May 24.

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant

Ilies Benotmane  1 , Aurélie Velay  2 , Gabriela Gautier-Vargas  1 , Jérôme Olagne  1 , Olivier Thaunat  2 , Samira Fafi-Kremer  3 , Sophie Caillard  4
Affiliations

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant

Ilies Benotmane et al. Kidney Int. 2022 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Serum-neutralizing IgG titers (log IC50) measured with a previously described in-house viral pseudoparticle-based assayin 3 groups of kidney transplant recipients. Orange circles denote titers measured at 28 days post-injection in patients (n = 63) who received Evusheld (300 mg; AstraZeneca), whereas yellow triangles indicate titers quantified at 31 days post-injection in patients (n = 39) who received Ronapreve (1200 mg; Roche Regeneron). Red squares denote titers measured at 27 days post-infection in patients (n = 14) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Dotted line represents the neutralizing positivity threshold (1.6 log IC50). Groups were compared with the Kruskal-Wallis test. The contingency graphs at the bottom of the figure indicate the percentages of patients with neutralizing activity in each group (with positive in red and negative in yellow; the percentage is reported in the middle). (b) Anti–receptor binding domain (RBD) IgG titers (binding antibody units [BAU]/ml, Abbott Architect) 28 days after Evusheld injection (300 mg) in 27 patients who did not receive Ronapreve™ before Evusheld. (c) Correlation between body mass index (kg/m2) and anti-RBD IgG titers (BAU/ml, Abbott Architect) 28 days after Evusheld injection (300 mg) in 27 patients who did not receive Ronapreve before Evusheld; r2 = 0.595. BMI, body mass index.
Figure 2
Figure 2
Correlation between anti–receptor binding domain (RBD) IgG (Abbott Architect) and neutralizing antibody titersin 3 groups of kidney transplant recipients. Orange circles denote titers measured at 28 days post-injection in patients (n = 63) who received Evusheld (300 mg; AstraZeneca), and yellow triangles indicate titers quantified at 31 days post-injection in patients (n = 39) who received Ronapreve (300 mg; Roche Regeneron). Red squares denote titers measured at 27 days post-infection in patients (n = 14) who were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). BAU, binding antibody units.
See this image and copyright information in PMC

Comment in

References

    1. Caillard S., Thaunat O. COVID-19 vaccination in kidney transplant recipients. Nat Rev Nephrol. 2021;17:785–787. - PMC - PubMed
    1. Planas D., Saunders N., Maes P., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–675. - PubMed
    1. UK Medicines and Healthcare products Regulatory Agency Regulatory approval of Evusheld (tixagevimabcil/cilgavimab) https://www.gov.uk/government/publications/regulatory-approval-of-evushe...
    1. Charmetant X., Espi M., Benotmane I., et al. Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. Sci Transl Med. 2022;14 - PMC - PubMed
    1. Kumar D, Hu Q, Samson R, et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. Am J Transplant. Published online March 10, 2022. - DOI - PMC - PubMed